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Abstract
Introduction: Statins and fibrates reduce monocyte release of proinflammatory cytokines, but it remains unknown whether this effect 
is sex dependent.
Material and methods: We retrospectively analysed age-, weight-, and lipid-matched populations of type 2 diabetic patients of both sexes, 
who, because of atherogenic dyslipidaemia, were treated with simvastatin (40 mg daily), fenofibrate (200 mg daily), or simvastatin plus 
fenofibrate. Monocyte release of tumour necrosis factor a (TNF-a), inteleukin-1b, interleukin-6, and monocyte chemoattractant protein-1 
(MCP-1), as well as circulating levels of high-sensitivity C-reactive protein (hsCRP) and free fatty acids (FFA) were assessed separately for 
men and women before and after 12 weeks of treatment.
Results: Baseline monocyte release of TNF-a, interleukin-1b, interleukin-6, and MCP-1, as well as plasma hsCRP and FFA levels were 
comparable in both sexes. Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-a, 
inteleukin-1b, interleukin-6, and MCP-1, with no difference between the treatment groups. The impact of simvastatin and fenofibrate 
administered alone on monocyte cytokine release and systemic inflammation did not differ between the men and women. The effect of 
simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male popula-
tion. The impact of simvastatin administered together with fenofibrate on TNF-a, interleukin-1b, and hsCRP was also stronger in the men 
than in the women, but the difference did not reach the level of significance.
Conclusions: The obtained results suggest that sex differences determine the strength of the monocyte-suppressing effect of simvastatin/ 
/fenofibrate combination therapy in type 2 diabetic patients with atherogenic dyslipidaemia. (Endokrynol Pol 2015; 66 (3): 224–230)
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Streszczenie
Wstęp: Mimo stwierdzenia, że statyny i fibraty zmniejszają wydzielanie cytokin prozapalnych, nie ustalono jak dotąd, czy wpływ tych 
leków na funkcję sekrecyjną monocytów zależy od płci pacjenta.
Materiał i metody: W badaniu dokonano retrospektywnej analizy wyników 69 chorych na cukrzycę typu 2, dobranych pod względem 
wieku, masy ciała i stężenia lipidów, którzy z racji współistniejącej dyslipidemii aterogennej byli leczeni simwastatyną (40 mg dziennie), 
fenofibratem (200 mg dziennie) oraz terapią skojarzoną oboma lekami (w powyższych dawkach). Wydzielanie przez aktywowane mono-
cyty czynnika martwicy nowotworów a (TNF-a), inteleukiny-1b, interleukiny 6 oraz białka chemotaktycznego dla monocytów-1 (MCP-1), 
jak również stężenie w osoczu białka C-reaktywnego (hsCRP) oraz wolnych kwasów tłuszczowych (FFA) oceniano oddzielnie dla kobiet 
i mężczyzn przed i po 12 tygodniach leczenia.
Wyniki: W warunkach wyjściowych wydzielanie cytokin prozapalnych oraz stężenie hsCRP i FFA były podobne u kobiet i mężczyzn. 
Simwastatyna, fenofibrat oraz łączne podawanie tych leków w zbliżonym stopniu hamowały uwalnianie przez aktywowane monocyty 
TNF-a, inteleukiny-1b, interleukiny-6 oraz MCP-1. Wpływ monoterapii simwastatyną i fenofibratem na wydzielanie cytokin prozapalnych 
oraz układowy stan zapalny nie różnił się pomiędzy kobietami i mężczyznami. W przypadku terapii skojarzonej obniżenie stężenia in-
terleukiny-6 oraz MCP-1 było silniej wyrażone u mężczyzn. Zmiany sekrecji TNF-a oraz interleukiny-1b wykazywały również zależność 
od płci pacjenta, jednak różnica ta nie osiągała poziomu znamienności statystycznej.
Wnioski: Uzyskane wyniki badania sugerują, że płeć ma znaczenie dla wpływu łącznego podawania simwastatyny i fenofibratu na wydzie-
lanie cytokin prozapalnych przez monocyty chorych z cukrzycą typu 2 i dyslipidemią aterogenną. (Endokrynol Pol 2015; 66 (3): 224–230)
Słowa kluczowe: płeć; simwastatyna; fenofibrat; dyslipidemia aterogenna; monocyty; cytokiny 
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Abbreviations
ACCORD Lipid — the Action to Control Cardiovascular 
Risk in Diabetes Lipid
CRP — C-reactive protein
FFA — free fatty acids
FIELD — the Fenofibrate Intervention in Endpoint 
Lowering in Diabetes study
HDL — high-density lipoprotein
HMG-CoA — 3-hydroxy-3-methylglutaryl coenzyme A
HOMA-IR — the homeostatic model assessment of 
insulin resistance ratio
hsCRP — high-sensitivity C-reactive protein
LDL — low-density lipoprotein
PPAR-a — peroxisome proliferator-activated receptor-a
TNF-a — tumour necrosis factor a
Introduction
Although cardiovascular disease is the major cause of 
death in women over the age of 65 years, the risk of 
heart disease in women is often underestimated due to 
the misperception that females are ‘protected’ against 
this disease [1, 2]. The under-recognition of coronary 
artery disease and its often non-typical clinical picture 
in women result in less aggressive therapy and the 
underrepresentation of women in clinical trials [1]. Hy-
percholesterolaemia is a major factor contributing to the 
incidence of coronary artery disease. Recent guidelines 
recommend achieving the same low-density lipopro-
tein (LDL) cholesterol levels in men and women [3]. 
How ever, the clinical benefits associated with hy-
polipidaemic agents seem to result in part from their 
extralipid, so-called pleiotropic effects of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (statins) and peroxisome proliferator-acti-
vated receptor-a (PPAR-a) activators (fibrates). These 
agents were found to produce anti-inflammatory, 
antioxidant, and antithrombotic properties, to regulate 
the growth and migration of smooth muscle cells and to 
improve endothelial function [4–7]. These effects may 
explain why statins are effective in reducing cardio-
vascular events in high-risk subjects without elevated 
LDL-cholesterol, including type 2 diabetes patients 
[8] and apparently healthy persons with elevated C-
reactive protein (CRP) levels [9], whereas fibrates are 
effective in patients with low low-density lipoprotein 
(HDL) cholesterol and metabolic syndrome [10, 11].
In the Action to Control Cardiovascular Risk in 
Diabetes Lipid (ACCORD Lipid) trial, the addition of 
fenofibrate to statin therapy was associated with a 18% 
lower number of cardiovascular events in men, and 
a non-statistically significant 38% higher number of 
cardiovascular events in women [12]. However, al-
though women exhibited slightly higher plasma lipids, 
higher frequency of non-white race, and less prior 
cardiovascular disease and microvascular disease, 
these differences do not seem to explain the significant 
differences in the primary outcome between men and 
women [12].
Nonetheless, subgroup analyses in the ACCORD 
Lipid [12] and the Fenofibrate Intervention in Endpoint 
Lowering in Diabetes study (FIELD) [13] trials indicate 
that fenofibrate is of the greatest benefit in decreasing 
cardiovascular events in patients with atherogenic 
dyslipidaemia. Previously, we observed that simvastatin 
and fenofibrate exhibited a similar effect on the secre-
tory function of human monocytes and lymphocytes 
and on systemic inflammation in type 2 diabetic subjects 
with mixed dyslipidaemia [14]. In the present study, 
we decided to investigate whether statin and/or fibrate 
action on cytokine release by activated monocytes in 
patients with diabetes mellitus and atherogenic dys-
lipidaemia is sex-dependent. 
Material and methods
We retrospectively analysed samples obtained from 
85 subjects (20–75 years old) with type 2 diabetes and 
atherogenic dyslipidaemia, who had been complying 
with lifestyle intervention and had been treated with 
metformin at the daily dose of 1.7–3.0 g, but not with 
any hypolipidaemic patients, for at least 12 weeks before 
the beginning of the study. Type 2 diabetes was defined 
as fasting plasma glucose at least 126 mg/dL or plasma 
glucose concentration 2 hours after a glucose load of at 
least 200 mg/dL; while atherogenic dyslipidaemia was 
defined as HDL cholesterol levels below 40 mg/dL in 
men and 50 mg/dL in women, and triglycerides at least 
150 mg/dL. Some of these patients were included in our 
previous study [14] and were eligible for the study, if 
they met the criteria of atherogenic dyslipidaemia. We 
excluded subjects with other forms of dyslipidaemias, 
any acute and chronic inflammatory processes, auto-
immune disorders, unstable coronary artery disease, 
myocardial infarction or stroke within 6 months pre-
ceding the study, untreated stage 2 or 3 hypertension 
(according to the 2003 European Society of Hyperten-
sion–European Society of Cardiology guidelines), 
symptomatic congestive heart failure, body mass index 
above 35 kg/m2, impaired renal or hepatic function, or 
malabsorption syndromes, as well as patients treated 
with insulin, oral antidiabetic drugs (with the exception 
of metformin), drugs known either to affect plasma lipid 
levels or to interact with statins and fibrates and with 
drugs that may affect inflammatory processes in the 
vascular wall (including non-steroid anti-inflammatory 
drugs, angiotensin-converting enzyme inhibitors, and 
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angiotensin II receptor blockers) within the 3 months 
preceding the study. 
The study protocol was approved by our institution-
al review board, and subjects gave written, informed 
consent to participate in the study. Simvastatin (40 mg 
daily), micronised fenofibrate (200 mg daily), or sim-
vastatin (40 mg daily) plus fenofibrate (200 mg daily) 
were administered once daily at bedtime for 12 weeks, 
and no changes in medication dosage were allowed 
throughout the study. To minimise the risk of eventual 
pharmacokinetic interactions between simvastatin and 
fenofibrate, both drugs were administered in 12-hour 
time intervals (between 8.00 and 9.00 a.m., and between 
8.00 and 9.00 p.m.). Compliance was monitored twice 
monthly by the number of tablets returned. During the 
study, all participants were also asked to follow lifestyle 
modification, the goals of which were a reduction in 
weight of at least 7%, total fat intake less than 30% of 
total energy intake, saturated fat intake less than 7% 
of energy consumed, cholesterol intake less than 200 
mg per day, an increase in fibre intake to 15 g per 1000 
kcal, and moderate to vigorous exercise for at least 30 
minutes per day. 
Laboratory investigations were performed at base-
line and at the end of the treatment. Venous blood 
samples were taken after a 12-hour overnight fast, in 
a quiet, temperature-controlled room (24–25°C) be-
tween 8.00 and 9.00 a.m. (to avoid possible circadian 
fluctuations in the parameters studied). Analysis was 
performed by a person blinded to subject identity and 
all clinical details. Total cholesterol, HDL cholesterol, 
LDL cholesterol, triglycerides, glucose, and insulin were 
assessed by routine laboratory techniques (bioMerieux 
France; Incstar Corporation, Stillwater, MN, USA; 
Beckman, Palo Alto, CA, USA; Linco Research Inc., St 
Charles, MO, USA). LDL levels were measured directly. 
Fasting plasma glucose and insulin levels were used to 
calculate the homeostatic model assessment — insulin 
resistance index (HOMA-IR) [fasting serum glucose 
(mg/dL) × fasting insulin level (mU/mL)/405]. Total 
non-esterified free fatty acids (FFA) were assessed by 
an enzymatic assay using reagents from Alpha Labora-
tories (Eastleigh, Hants, UK). Circulating levels of CRP 
were determined using a high-sensitivity monoclonal 
antibody assay (hsCRP) (MP Biomedicals, Orangeburg, 
NY). Glycated haemoglobin was determined using 
a DCA 2000 analyser (Bayer Ames Technicon, Tarrytown, 
NY, USA). Cultures of phytohemagglutinin-stimulated 
T cells and lipopolysaccharide-stimulated monocytes 
were performed in triplicate as described previously 
[15, 16]. Monocyte release of TNF-a, inteleukin-1b, 
interleukin-6, and MCP-1 were estimated using com-
mercial ELISA kits (R&D Systems, McKinley Place N.E. 
Minneapolis, MN), according to the manufacturer ’s 
instructions. The minimum detectable levels for the 
assessed cytokines were: 4.4 pg/mL (TNF-a), 1.0 pg/mL 
(inteleukin-1b), 3.8 pg/mL (interleukin-6), and 5.0 pg/mL 
(MCP-1). Intra- and inter-assay coefficients of variation 
were less than 5.8 and 8.6%, respectively.
The Kolmogorov-Smirnov test was used as the first 
statistical analysis approach to verify data distribution 
normality. Because of skewed distributions, values for 
the HOMA-IR, triglycerides, hsCRP, and cytokines 
were natural-log transformed to meet the assumptions 
of parametric tests. Comparisons between the groups 
were made by the t test for independent samples. Stu-
dent’s paired t-test was applied to compare pre- and 
post-treatment data within the same group. Correla-
tions between the study parameters were calculated 
using Kendall’s t test. Statistical significance was as-
sumed at p < 0.05. 
Results
In order to obtain age-, weight-, and plasma lipid-
matched populations of men and women, in the 
present study, we chose to analyse the samples of 69 
patients: 12 men and 11 women treated with simv-
astatin, 12 men and 10 women receiving fenofibrate, 
and 14 men and 10 women treated with simvastatin/ 
/fenofibrate combination. The data of the remaining 
patients participating in the study were not included 
in the final analyses. At study entry there were also 
no differences between the populations of men and 
women in terms of medical background and safety 
parameters (Table I). Both populations differed in waist 
circumference. Baseline monocyte release of TNF-a, 
interleukin-1b, interleukin-6, and MCP-1, as well as 
plasma hsCRP and FFA levels did not differ between 
the men and the women. 
Neither drop-outs nor serious adverse events were 
observed throughout the study in the analysed groups 
of patients. All safety parameters remained within 
normal limits.
In both diabetic men and women with atherogenic 
dyslipidaemia complying with lifestyle modification 
and treated with metformin, simvastatin (Table II), 
fenofibrate (Table III), and simvastatin/fenofibrate com-
bination therapy (Table IV) decreased total cholesterol, 
LDL cholesterol and triglycerides, plasma hsCRP and 
FFA, and monocyte release of TNF-a, interleukin-1b, 
interleukin-6 and MCP-1, as well as increased HDL cho-
lesterol. Moreover, fenofibrate alone or in combination 
with simvastatin reduced plasma glucose, HOMA-IR, 
and glycated haemoglobin.
If the patients were treated exclusively with simvas-
tatin and fenofibrate, the monocyte-suppressing effect 
was similar for men and women (Tables II and III). In 
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the case of simvastatin/fenofibrate combination therapy, 
the treatment-induced changes in monocyte release 
of interleukin-6 and MCP-1 were more pronounced in 
the men than in the women (Table IV). The impact of 
simvastatin/fenofibrate combination therapy on TNF-a, 
interleukin-1b and hsCRP was also stronger in the 
male population, but the difference did not reach the 
level of significance (p = 0.086 for TNF-a, p = 0.075 for 
interleukin-1b, and p = 0.096 for hsCRP).
In both men and women, simvastatin/fenofibrate 
combination therapy stronger than fenofibrate reduced 
circulating levels of total cholesterol, LDL cholesterol 
and triglycerides, as well as was superior to simva-
statin in affecting total cholesterol, HDL cholesterol 
triglycerides, glucose and HOMA-IR, and glycated 
haemoglobin (Table IV). Irrespectively of sex, there were 
no differences between simvastatin and fenofibrate in 
the strength of their action on monocyte release of the 
investigated cytokines. Irrespectively of sex, the effect 
of combination therapy on plasma hsCRP was more 
pronounced than that of simvastatin or fenofibrate 
alone. In the men, the effect of simvastatin/fenofibrate 
combination therapy on interleukin-6 and MCP-1 was 
stronger than in the male patients treated with only 
one of these drugs (Table IV). 
At entry, in both sexes, there was a correlation be-
tween cytokine release and plasma hsCRP levels (men: 
r values between 0.30 [p < 0.05] and 0.43 [p < 0.01]; 
women: r values between 0.35 [p < 0.05] and 0.47 
[p < 0.001]) as well as between cytokine release and 
HOMA-IR (men: r values between 0.37 [p < 0.01] and 
0.48 [p < 0.001]; women: r values between 0.39 [p < 0.05] 
and 0.47 [p < 0.01]).
In men and women the effect of hypolipidaemic 
treatment on monocyte release and plasma hsCRP 
did not correlate with the treatment-induced changes 
in plasma lipids. In both sexes there were correlations 
between the impact of hypolipidaemic treatment on 
cytokine release and its effect on hsCRP (simvasta-
tin — men: r values between 0.46 [p < 0.01] and 0.59 
[p < 0.001], women: r values between 0.43 [p < 0.01] and 
0.58 [p < 0.001]; fenofibrate — men: r values between 
0.43 [p < 0.01] and 0.57 [p < 0.001], women: r values 
between 0.43 [p < 0.01] and 0.55 [p < 0.001]; combina-
tion therapy: men: r values between 0.46 [p < 0.01] 
and 0.62 [p < 0.001], women: r values between 0.49 
[p < 0.001] and 0.60 [p < 0.001]). The treatment-induced 
changes in monocyte release of TNF-a, interleukin-1b, 
interleukin-6 and MCP-1 release and plasma hsCRP 
Table I. Baseline characteristics of the participants
Tabela I. Wyjściowa charakterystyka pacjentów
Women Men
Number of patients 31 38
Age [years; mean (SD)] 53.0 (2.3) 53.4 (2.4)
Smokers (%) 19 21
Body mass index [kg/m2; mean (SD)] 28.1 (3.0) 28.7 (2.9)
Waist circumference [cm; mean (SD)] 95 (5) 101 (6)**
Grade 1 hypertension (%) 68 73
Intima-media thickness [mm; mean (SD)] 0.91 (0.21) 0.94 (0.18)
Total cholesterol [mg/dL; mean (SD)] 210 (19) 218 (16)
LDL cholesterol [mg/dL; mean (SD)] 121 (12) 128 (14)
HDL cholesterol [mg/dL; mean (SD)] 38 (4) 34 (4)
Triglycerides [mg/dL; mean (SD)] 228 (31) 240 (35)
Glucose [mg/dL; mean (SD)] 146 (11) 148 (12)
HOMA-IR [mean (SD)] 9.8 (1.1) 10.5 (1.3)
Glycated haemoglobin [%; mean (SD)] 7.0 (0.5) 7.2 (0.6)
hsCRP [mg/L; mean (SD)] 3.4 (0.6) 3.2 (0.5)
FFA [µmol/L; mean (SD)] 416 (57) 447 (61)
TNF-a [pg/mL; mean (SD)] 1842 (240) 1710 (285)
Interleukin-1b [pg/mL; mean (SD)] 143 (19) 155 (26)
Interleukin-6 [ng/mL; mean (SD)] 10.1 (3.0) 11.2 (2.8)
MCP-1 [ng/mL; mean (SD)] 20.4 (3.8) 22.2 (3.4)
**p < 0.01 vs. women
Table II. The effect of 12-week simvastatin treatment on 
plasma lipids, glucose metabolism markers, and circulating 
levels of high sensitivity CRP, free fatty acids, and monocyte 
cytokine release in type 2 diabetic men and women with 
atherogenic dyslipidaemia
Tabela II. Wpływ 12-tygodniowego stosowania simwastatyny 
na stężenie lipidów, markery gospodarki węglowodanowej, 
stężenie CRP i wolnych kwasów tłuszczowych oraz 
wydzielanie cytokin prozapalnych przez aktywowane 
monocyty kobiet i mężczyzn z cukrzycą typu 2 oraz 
dyslipidemią aterogenną
Women 
(n = 11)
Men 
(n = 12)
DTotal cholesterol [mg/dL; mean (SD)] –54 (18)*** –49 (15)***
DLDL cholesterol [mg/dL; mean (SD)] –42 (14)*** –39 (12)***
DHDL cholesterol [mg/dL; mean (SD)] 7 (4)* 5 (3)*
DTriglycerides [mg/dL; mean (SD)] –31 (18)* –37 (20)*
DGlucose [mg/dL; mean (SD)] –5 (7) –5 (6)
DHOMA-IR [%; mean (SD)] –1.0 (0.9) –1.2 (1.1)
DGlycated haemoglobin [%; mean (SD)] –0.2 (0.4) –0.1 (0.4)
DhsCRP [mg/L; mean (SD)] –1.6 (0.5)*** –1.3 (0.5)***
DFFA [µmol/L; mean (SD)] –156 (43)*** –169 (39)***
DTNF-a [pg/mL; mean (SD)] –639 (178)** –680 (120)**
DInterleukin-1b [pg/mL; mean (SD)] –58 (6)*** –64 (7)***
DInterleukin-6 [ng/mL; mean (SD)] –3.4 (0.7)** –3.5 (0.6)**
DMCP-1 [ng/mL; mean (SD)] –4.8 (1.2)** –5.6 (1.6)**
*p < 0.05; **p < 0.01; ***p < 0.001 post-treatment vs. baseline value
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correlated with the degree of reduction in FFA (simvas-
tatin — men: r values between 0.32 [p < 0.05] and 0.55 
[p < 0.001], women: r values between 0.34 [p < 0.05] 
and 0.52 [p < 0.001]; fenofibrate — men: r values 
between 0.44 [p < 0.01] and 0.58 [p < 0.001], women: 
r values between 0.46 [p < 0.01] and 0.56 [p < 0.001]; com-
bination therapy: men: r values between 0.47 [p < 0.01] 
and 0.61 [p < 0.001], women: r values between 0.49 
[p < 0.001] and 0.59 [p < 0.001]), and in the case of fenof-
ibrate and simvastatin/fenofibrate combination therapy 
with the effect on HOMA-IR (fenofibrate — men: 
r values between 0.35 [p < 0.05] and 0.50 [p < 0.001], 
women: r values between 0.31 [p < 0.05] and 0.51 
[p < 0.001]; combination therapy — men: r values 
between 0.37 [p < 0.01] and 0.60 [p < 0.001], women: 
r values between 0.40 [p < 0.01] and 0.56 [p < 0.001]).
Discussion
Probably the most important finding of our study 
is that the effect of simvastatin/fenofibrate combina-
tion therapy on monocyte release of proinflammatory 
cytokines is more pronounced in men than in women 
with type 2 diabetes and atherogenic dyslipidaemia. 
In the whole population of investigated patients, the 
monocyte-suppressing effect was similar in the patients 
treated with statin/fenofibrate combination therapy 
and in those receiving only one of these drugs. But 
only in the men, the effect of simvastatin/fenofibrate 
combination therapy on interleukin-6 and MCP-1 was 
more pronounced than that of simvastatin or ezetimibe 
administered alone.
These findings may partially explain why, in the 
ACCORD Lipid trial, fenofibrate added to a HMG- 
-CoA reductase inhibitor reduced cardiovascular risk 
exclusively in men [12]. Interestingly, in the remaining 
treatment groups, sex differences did not determine the 
effect of hypolipidaemic therapy on monocyte secretory 
Table III. The effect of 12-week fenofibrate treatment on 
plasma lipids, glucose metabolism markers, and circulating 
levels of high sensitivity CRP, free fatty acids, and monocyte 
cytokine release in type 2 diabetic men and women with 
atherogenic dyslipidaemia
Tabela III. Wpływ 12-tygodniowego stosowania fenofibratu 
na stężenie lipidów, markery gospodarki węglowodanowej, 
stężenie CRP i wolnych kwasów tłuszczowych oraz 
wydzielanie cytokin prozapalnych przez aktywowane 
monocyty kobiet i mężczyzn z cukrzycą typu 2 oraz 
dyslipidemią aterogenną
Women 
(n = 10)
Men 
(n = 12)
DTotal cholesterol [mg/dL; mean (SD)] –27 (10)* –25 (8)*
DLDL cholesterol [mg/dL; mean (SD)] –20 (8)* –21 (9)*
DHDL cholesterol [mg/dL; mean (SD)] 9 (5)** 9 (4)**
DTriglycerides [mg/dL; mean (SD)] –65 (17)*** –60 (19)***
DGlucose [mg/dL; mean (SD)] –14 (6)** –15 (7)**
DHOMA-IR [%; mean (SD)] –4.1 (0.9)** –4.3 (1.1)***
DGlycated haemoglobin [%;  
mean (SD)]
–0.8 (0.6)** –0.7 (0.5)**
DhsCRP [mg/L; mean (SD)] –1.6 (0.5)*** –1.2 (0.4)***
DFFA [µmol/L; mean (SD)] –192 (31)*** –176 (26)***
DTNF-a [pg/mL; mean (SD)] –570 (172)** –601 (196)**
DInterleukin-1b [pg/mL; mean (SD)] –60 (12)*** –68 (11)***
DInterleukin-6 [ng/mL; mean (SD)] –3.2 (0.5)** –3.5 (0.6)**
DMCP-1 [ng/mL; mean (SD)] –5.7 (1.0)** –6.5 (1.3)**
*p < 0.05; **p < 0.01; ***p < 0.001 post-treatment vs. baseline value
Table IV. The effect of 12-week simvastatin/fenofibrate 
combination therapy on plasma lipids, glucose metabolism 
markers, and circulating levels of high sensitivity CRP, free 
fatty acids, and monocyte cytokine release in type 2 diabetic 
men and women with atherogenic dyslipidaemia
Tabela IV. Wpływ 12-tygodniowego stosowania simwastatyny 
wraz z fenofibratem na stężenie lipidów, markery gospodarki 
węglowodanowej, stężenie CRP i wolnych kwasów 
tłuszczowych oraz wydzielanie cytokin prozapalnych przez 
aktywowane monocyty kobiet i mężczyzn z cukrzycą typu 2 
oraz dyslipidemią aterogenną
Women 
(n = 10)
Men 
(n = 14)
DTotal cholesterol [mg/dL;  
mean (SD)]
–67 (14)***&^^^ –70 (12)***&^^^
DLDL cholesterol [mg/dL;  
mean (SD)]
–43 (12)***^^^ –47 (11)***^^^
DHDL cholesterol [mg/dL;  
mean (SD)]
13 (6)***& 11 (5)***&
DTriglycerides [mg/dL;  
mean (SD)]
–85 (15)***&&&^ –79 (13)***&&&^
DGlucose [mg/dL; mean (SD)] –13 (4)**& –14 (5)**&
DHOMA-IR [%; mean (SD)] –3.8 (0.8)***&&& –4.1 (1.0)***&&&
DGlycated haemoglobin  
[%; mean (SD)]
–0.8 (0.7)**& –0.9 (0.6)**& 
DhsCRP [mg/L; mean (SD)] –2.3 (0.5)***&&^^ –1.9 (0.4)*** &&^^
DFFA [µmol/L; mean (SD)] –189 (41)*** –210 (37)***
DTNF-a [pg/mL; mean (SD)] –620 (202)*** –780 (155)***
DInterleukin-1b [pg/mL;  
mean (SD)]
–58 (14)*** –68 (15)***
DInterleukin-6 [ng/mL;  
mean (SD)]
–3.6 (0.7)*** –4.6 (0.7)***#&^
DMCP-1 [ng/mL; mean (SD)] –6.1 (1.9)*** –8.3 (2.1)***#&^
**p < 0.01; ***p < 0.001 post-treatment vs. baseline value 
#p < 0.05 vs. women 
&p < 0.05; &&p < 0.01; &&&p < 0.001 vs. the effect of simvastatin in the patients 
of the same sex
^p < 0.05; ^^p < 0.01; ^^^p < 0.001 vs. the effect of fenofibrate in the 
patients of the same sex
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function and low-grade inflammation, and in line with 
this observation the impact of statins [8, 9] and fibrates 
[10, 11, 13] on the investigated end-points in other large 
clinical trials did not differ between men and women.
All participants of our study met the criteria of 
atherogenic dyslipidemia and these individuals may 
be the best candidates for statin/fibrate combination 
therapy. In the ACCORD Lipid trial, patients with HDL 
cholesterol below 34 mg/dL and triglycerides above 
204 mg/dL gained the greatest clinical benefit from add-
ing fenofibrate to statin therapy [12]. Certainly, there 
are some important differences between our study and 
the ACCORD Lipid trial. Our study included exclu-
sively subjects with recently diagnosed and previously 
untreated dyslipidaemia, who were at once simulta-
neously treated with simvastatin and fenofibrate. In 
turn, in the mentioned clinical trial, diabetes lasted on 
average 10 years, dyslipidaemia had not always been 
present before the beginning of the study, participants 
suffered from various coexisting disorders, had already 
been treated with a HMG-CoA reductase inhibitor, and 
statin doses differed between patients.
Baseline monocyte cytokine release did not differ be-
tween the men and women, and this finding is in contrast 
to the findings of other authors [17–20] who observed 
higher monocyte production and plasma levels of pro-
inflammatory cytokines in men. These differences may 
be explained by various inclusion criteria, which were 
very strict in our study. The male and female participants 
of our study were characterised by similar clinical and 
laboratory characteristics (with the exception of waist 
circumference), which enabled us to reduce the possi-
ble impact of other disorders or concomitant therapies. 
Alternatively, as lymphocyte release of proinflammatory 
cytokines is sex-dependent [Krysiak et al., unpublished 
observations], higher circulating levels of proinflamma-
tory cytokines in men may reflect sex-dependent differ-
ences in the function of other types of cells.
A complex proatherogenic action of TNF-a, inteleu-
kin-1b, interleukin-6, and MCP-1 [21, 22], as well as the 
fact that monocytes are the primary inflammatory cell 
type that infiltrate early atherosclerotic plaques, playing 
a variety of roles in atherosclerotic plaque development 
and its clinical sequelae [23, 24], suggest that the mono-
cyte-suppressing effect of simvastatin and fenofibrate 
administered alone or in combination may be clinically 
relevant for both men and women. Considering that 
even small differences in the investigated variables may 
be related to various risks of cardiovascular disorders, 
as it was found in the case of TNF-a and interleukin-
1b, combined administration of a statin and a fibrate 
may bring important clinical benefits to type 2 diabetic 
men with atherogenic dyslipidaemia, who have high 
cardiovascular risk [25].
The lack of a correlation between the effect on cy-
tokine release and the extent of lipid-lowering action 
of simvastatin and/or fenofibrate, shown in both sexes, 
indicates that the impact on monocyte secretory func-
tion belongs to the pleiotropic effects of these agents. 
This effect, irrespectively of gender, is reciprocally in-
terrelated with their action on systemic inflammation, 
and the latter action is probably partially secondary 
to statin- and/or fibrate-induced changes in monocyte 
secretory function. 
Irrespectively of gender, the effect of hypolipi-
daemic agents on monocyte cytokine release and 
systemic inflammation correlated with their action 
on FFA and, in the patients treated with fenofibrate 
or simvastatin/fenofibrate combination therapy, with 
an improvement in insulin sensitivity. In the case 
of fenofibrate, the presence of these correlations is 
a logical consequence of the involvement of FFA in the 
development of insulin resistance in both men and 
women [26], as well as the role of endogenous ligands 
for PPAR-a [27]. Finding that a similar reduction in 
FFA was induced by simvastatin is in agreement 
with the hypothesis that the molecular mechanisms 
of the action of statins and fibrates partially overlap 
[28, 29]. An inhibitory effect of simvastatin-induced 
inhibition of protein prenylation on the activity of 
glucose transporter 4 [30], responsible for insulin-
regulated glucose transport into the cell [31], may 
explain why, despite a reduction in FFA, simvastatin 
did not improve insulin sensitivity.
Interestingly, the effect of simvastatin and fenofi-
brate on cytokine release correlated better with the 
clinical outcome of the ACCORD Lipid trial than 
their action on circulating levels of hsCRP. Although 
this protein is regarded as one of the most significant 
risk factors for cardiovascular disease and is directly 
involved in atherogenesis [32], unlike the results of 
the ACCORD Lipid trial, the effect of simvastatin 
and fenofibrate on hsCRP was additive in both sexes, 
and only insignificantly stronger in the men than the 
women.
This study has some limitations. Firstly, the study in-
cluded only a limited number of patients and measured 
only surrogates of outcome, and hence the findings 
must be interpreted with caution. Secondly, our study 
was a retrospective analysis of the stored samples. Fur-
thermore, all participants were treated with metformin, 
and therefore it is not certain whether the investigated 
treatment options produce similar effects in patients 
treated with other hypoglycaemic agents. Finally, all 
our patients had coexistent type 2 diabetes. Therefore, 
the question of whether a similar effect is observed in 
insulin-resistant patients with less expressed glucose 
metabolism abnormalities remains open.
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Conclusions
Our study has shown for the first time that the effect 
of simvastatin/fenofibrate combination therapy, but not 
of simvastatin or fenofibrate administered alone, on 
monocyte cytokine release in type 2 diabetes patients 
with atherogenic dyslipidaemia differs between men 
and women. This finding, requiring confirmation in 
future studies, suggests that sex differences partially 
determine the strength of the monocyte-suppressing 
effect of simvastatin/fenofibrate combination therapy 
in this group of patients.
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